Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Teva Pharmaceutical Industries Limited

TEVA

Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Last trade $42.20
Day change -$0.37 (-0.87%)
Day range $41.59 – $42.61
Volume 4,321,744
Market cap $49.67B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$49.67B
Price / earnings
97.78×
Price / book
6.23×
Price / sales
2.88×
EV / sales
3.62×
EV / EBITDA
14.23×

Profitability

Earnings per share
$0.44
Return on assets
1.27%
Return on equity
6.37%
Dividend yield
0%

Liquidity and leverage

Debt / equity
2.1×
Current ratio
0.97×
Quick ratio
0.76×
Cash ratio
0.27×

Cash flow

Price / cash flow
28.06×
Price / free cash flow
40.19×
Free cash flow
$1.24B

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for TEVA, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$4.4B$4.14B$3.98B$4.71B$4.48B$4.18B$3.89B$4.23B
Cost of revenue$1.96B$1.99B$2.01B$2.06B$2.18B$2.07B$2.01B$2.11B
Gross profit$2.44B$2.15B$1.97B$2.66B$2.3B$2.1B$1.88B$2.12B
Selling, general and administrative$1.01B$1.03B$1B$1.12B$973M$959M$919M$952M
Research and development$297M$970M$222M$267M$256M$244M$247M$247M
Total operating expenses$1.73B$2.38B$1.32B$2.36B$1.42B$1.65B$1.36B$2.15B
Operating income$714M-$231M$652M$299M$882M$455M$521M-$29M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes$300M-$455M$437M$80M$646M$203M$296M-$247M
Income taxes$66M$121M$67M-$390M$214M-$78M$74M$28M
Net income$234M-$576M$370M$481M$434M$282M$222M-$275M
Net income attributable to common shareholders$234M-$576M$370M$480M$434M$282M$216M-$217M
EBITDA$1.45B$409M$997M$1.52B$1.32B$1.15B$950M$1.18B
Basic earnings per share$0.20-$0.49$0.32$0.42$0.38$0.25$0.19-$0.19
Diluted earnings per share$0.20-$0.49$0.31$0.41$0.37$0.24$0.18-$0.19

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Global Injectables Market is Anticipated to Surpass USD 1 Trillion Mark by 2034 | DelveInsight

The global injectables market is projected to grow from USD 765 billion in 2025 to USD 1.6 trillion by 2034, with a CAGR of approximately 9%. Growth is driven by rising adoption of biologics, biosimilars, GLP-1 therapies, and advances in drug-delivery technologies like prefilled syringes and auto-injectors. North America leads with 39% market share, while Asia-Pacific represents the fastest-expanding region. Key developments include West Pharmaceutical Services' Dublin expansion and Fresenius Kabi's U.S. manufacturing collaboration.

GlobeNewswire Inc.

Peptide Therapeutics Market: Global Size, Share, Trends and Forecast to 2036 | Set to Reach $229.32 Billion as GLP-1, Oral Peptides, Radioligands, and Generics Fuel Growth

The global peptide therapeutics market is projected to grow from $112.20 billion in 2026 to $229.32 billion by 2036 at a 7.4% CAGR, driven by GLP-1 and incretin therapies, oral peptides, radioligands, and generic competition. Eli Lilly and Novo Nordisk lead the market with blockbuster incretin products, while emerging opportunities include oral macrocyclic peptides, radioligands, and generic semaglutide following patent expiry in major markets.

GlobeNewswire Inc.

Paracetamol Market to Exceed USD 15 Billion by 2032 Driven by Rising Demand for Pain Relief and Fever Management, Reports Mordor Intelligence

The global paracetamol market is projected to grow from USD 12.05 billion in 2026 to USD 15.39 billion by 2032, registering a CAGR of 4.12%. Growth is driven by rising demand for pain and fever management, expanding over-the-counter medicine access, and manufacturing capacity investments. Asia-Pacific is the fastest-growing region, while North America maintains the largest market share at 33.68%. However, generic competition and pricing pressure continue to influence supplier margins.

The Motley Fool

Teva's 3 Key Branded Drugs Grew Sales 33% Last Quarter. Is This Turnaround Stock a Buy Right Now?

Teva Pharmaceuticals is executing a successful turnaround strategy, shifting from generics to higher-margin branded therapies. Its three key drugs (Austedo, Ajovy, Uzedy) grew sales 33% year-over-year to $1.1 billion in Q3, while gross margins improved to 55.5%. The company has paid down $12 billion in debt since 2019 and received investment-grade ratings. However, overall Q3 revenue declined 2% due to generic drug competition, and the company faces headwinds from commoditized generics. Despite recent gains, the stock trades at less than 21x forward earnings.

Zacks Investment Research

Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock Up

Teva Pharmaceutical Industries beat Q3 earnings expectations with adjusted EPS of 86 cents versus 72 cents consensus, driven by strong sales from branded drugs Austedo, Ajovy, and Uzedy. The company raised its 2026 revenue guidance to $16.7-$17.0 billion and increased forecasts for key branded drugs, though generic drug revenues declined significantly due to increased competition.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Nov 27, 2017$0.085Dec 12, 2017recurring
Aug 25, 2017$0.085Sep 14, 2017recurring
Jun 1, 2017$0.34Jun 22, 2017recurring
Feb 28, 2017$0.34Mar 20, 2017recurring
Dec 1, 2016$0.34Dec 20, 2016recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jul 1, 20042-for-1forward split
Dec 6, 20022-for-1forward split